Skip to content
value.today

IVIEW Therapeutics, Inc.

Total raised
$39 M
2 rounds on record
Latest round
$9 M
May 2024
First round on record
Feb 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of IVIEW Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$9 MNo. 2$2 to $10 million

IVIEW Therapeutics, Inc.: Raise no. 2, May 2024

Investors in this round

5 investors had bought by the notice of Jun 10, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $15 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bo Liang · Executive Officer, Director
  • Houman Hemmati · Executive Officer, Director
  • Wei Wang · Executive Officer, Director
  • Bin He · Director
  • Jingjie Li · Director
  • Qi Zhu · Director
  • Xiaolu Sun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bo Liang, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 10, 2025. Read the notice at the SEC.

equitySEC
Feb 2021$30 MNo. 1$10 to $50 million

IVIEW Therapeutics, Inc.: Raise no. 1, Feb 2021

Investors in this round

15 investors had bought by the notice of Jan 12, 2022: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bo Liang · Executive Officer, Director
  • Qi Zhu · Executive Officer, Director
  • Wei Wang · Executive Officer, Director
  • Bin J He · Director
  • John J Baldwin · Director
  • Tao J Du · Director
  • Xiaolu J Sun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bo Liang, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 12, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • IVIEW Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2025).

    SEC Form D · Jun 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2025

That is all the official record says: IVIEW Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of IVIEW Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by IVIEW Therapeutics, Inc.
NameRoleNamed in
Bo LiangExecutive officerJun 2025
Houman HemmatiExecutive officerJun 2025
Wei WangExecutive officerJun 2025
Qi ZhuExecutive officerJan 2022
Bin HeDirectorJun 2025
Bo LiangDirectorJun 2025
Houman HemmatiDirectorJun 2025
Jingjie LiDirectorJun 2025
Qi ZhuDirectorJun 2025
Wei WangDirectorJun 2025
Xiaolu SunDirectorJun 2025
Bin J HeDirectorJan 2022
John J BaldwinDirectorJan 2022
Tao J DuDirectorJan 2022
Xiaolu J SunDirectorJan 2022
Jun J DuDirectorMar 2021